Shattuck Labs Drops 15% Despite Citigroup Upgrade and Positive Trial Data

Key Facts

1Citigroup significantly raised its price target for Shattuck Labs from $7.00 to $18.00 while maintaining a Buy rating.

2Lead candidate SL-325 demonstrated a favorable safety profile and low immunogenicity in Phase 1 clinical trials.

3Shattuck Labs stock fell 14.85% to $3.90 despite positive trial data and an analyst upgrade, reflecting high investor expectations.

In a move reflecting the disconnect between analyst valuations and market reality in the biotech sector, Shattuck Labs shares experienced sharp volatility following pivotal updates. Citigroup significantly raised its price target for the stock from $7.00 to $18.00 while maintaining a Buy rating, after the lead candidate SL-325 demonstrated a favorable safety profile in Phase 1 clinical trials. However, Shattuck Labs stock fell 14.85% to $3.90 despite the positive data, suggesting a 'sell the news' reaction from investors.

This decline occurs as the broader biotechnology sector often faces profit-taking following clinical milestones. Compared to other small-cap biopharma peers, Phase 1 data releases frequently trigger double-digit volatility, per market data. Citigroup's target hike of nearly 157% positions STTK as a significant outlier in terms of potential upside, provided that investor sentiment regarding clinical trial risks stabilizes in the coming quarters.

Traders should watch the current support level at $3.90 (close June 11, 2026) to see if the stock can establish a floor. Regarding macro catalysts, the market is looking toward the Fed Barr Speech on June 6, 2026, which may influence risk appetite for growth stocks. Future updates on the low immunogenicity of SL-325 will remain the primary fundamental driver for the instrument's long-term recovery.